---

$17.85

-0.2700 ( -1.49% ) 380.3K

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-07-09	Sale	-1610.00	Dunn Edmund
2024-06-13	Sale	-22100.00	Behbahani Ali
2024-06-13	Sale	-22100.00	Siu Christine
2024-06-13	Sale	-22100.00	SCHIFF ANDREW N
2024-06-13	Sale	-22100.00	Skvarka Jan
2024-06-13	Sale	-22100.00	Manning Anthony M.
2024-06-13	Sale	-22100.00	Blackwell Kimberly
2024-06-05	Sale	-1207.00	Dunn Edmund
2024-06-05	Sale	-40000.00	Nickson Philip
2024-06-05	Sale	-40000.00	Townson Sharon